New combo therapy aims to fight inoperable liver cancer
Disease control
Recruiting now
This phase 3 trial is testing whether adding two drugs—camrelizumab (an immunotherapy) and apatinib (a targeted therapy)—to a standard liver cancer procedure called TACE can help people with liver cancer that cannot be removed by surgery. The study will enroll 101 participants wi…
Phase: PHASE3 • Sponsor: Guohui Xu • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC